Alpha DNA Investment Management’s Akamai AKAM Stock Holding History

Alpha DNA Investment Management’s Portfolio AKAM Stock Details AKAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,219	Closed	-$973K	–	197
2023 Q4	$973K	Buy	+8,219	New	+$914K	0.38%	47
2021 Q2	–	Sell	-130	Closed	-$12K	–	119
2021 Q1	$12K	Buy	130 +19	+17%	+$1.96K	0.01%	278
2020 Q4	$11K	Buy	+111	New	+$11.6K	0.01%	294

Other funds holding AKAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Alpha DNA Investment Management's AKAM Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of Akamai (AKAM) in Q1 2024, closing a stake of 8,219 shares — an estimated $973K sold.

Alpha DNA Investment Management first reported a position in AKAM in Q4 2020 and held it in 3 quarters. The position peaked at $973K in Q4 2023. 760 funds tracked by Wall St. Rank hold AKAM as of Q1 2024.

Alpha DNA Investment Management reported no remaining Akamai position as of Q1 2024 after selling out during the quarter.
Alpha DNA Investment Management sold 8,219 Akamai shares in Q1 2024, an estimated $973K.
Alpha DNA Investment Management first reported a position in Akamai in Q4 2020 and held it in 3 quarters.
Alpha DNA Investment Management's Akamai position peaked at $973K in Q4 2023.
760 funds tracked by Wall St. Rank held Akamai as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.